Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in R/R B-cell Malignancies
NCT04011293Phase 1Unknown
- Sponsor
- Shandong University
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Shandong University. Primary endpoints: Number of participants with treatment-related adverse events at 24 months and Overall remission rate at 3 months. Status: unknown.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04011293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011293.